Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Latest Information Update: 14 Jan 2026
At a glance
- Drugs Sonrotoclax (Primary) ; Zanubrutinib
- Indications B-cell leukaemia; Chronic lymphocytic leukaemia
- Focus Therapeutic Use
Most Recent Events
- 14 Jan 2026 New trial record